AMP Amphion Innovations Plc

 

TIDMAMP 
 
RNS Number : 2990Q 
Amphion Innovations PLC 
07 April 2009 
 

 
 
Directors' Dealings 
Directors Receive Shares in Lieu of Fees 
 
 
London and New York, 7 April 2009 - Amphion Innovations plc (LSE: AMP), the 
developer of medical and technology businesses, today announces that Board 
members Richard Mansell-Jones, Anthony Henfrey, and R. James Macaleer have used 
their  directors' fee for the period 1 October to 31 December 2008, to subscribe 
to the convertible promissory note offering for a total of GBP24,625.  For the 
period 1 January to 31 March 2009, the same directors, in lieu of their 
directors' fees, received ordinary shares priced at 11.14p, being the average 
price for the five days leading up to the market close on 31 March 2009. 
The Convertible Promissory Notes are convertible between 31 December 2008 to 31 
December 2013 into fully paid Ordinary Shares of 1 pence each in the capital of 
the Company at a conversion price of 18 pence per Ordinary Share and pay 
interest of 7 per cent annually until conversion. In addition, for each Note 
issued, the Company also issued 1.11 warrants to each subscriber of the Notes, a 
ratio of one warrant for every five shares issuable upon conversion. Each 
warrant will entitle the holder to subscribe for one Ordinary Share at 20 pence 
per Ordinary Share. 
Richard Mansell-Jones, Chairman of Amphion, received 110,519 ordinary shares, 
bringing his total holdings of the Company to 2,967,107 representing 2.26% of 
the Company's enlarged issued ordinary share capital. 
 
 
Anthony Henfrey received 55,259 ordinary shares, bringing his total holding of 
the Company to 1,065,735 representing 0.81% of the Company's issued ordinary 
share capital. 
 
 
R. James Macaleer received 55,259 ordinary shares, bringing his total holding of 
the Company to 22,364,178 representing 17.01% of the Company's issued ordinary 
share capital. 
 
 
Admission of the 221,037 new ordinary shares, ranking pari passu, is expected 
on 15 April 2009.  Following this allotment the total issued share capital of 
the Company will increase to 131,474,871 ordinary shares. 
 
 
 
 
For further information please contact 
Amphion Innovations plc 
 Charlie Morgan, Director of Communications 
 +1 
(212) 210 6224 
Cardew Group 
 Tim Robertson/ Jamie Milton/ Matthew Law 
 +44 20 7930 0777 
Charles Stanley (Nominated Adviser) 
 Mark Taylor/ Freddy Crossley 
 +44 20 
7149 6000 
About Amphion Innovations plc 
 
 Amphion (LSE: AMP) builds shareholder value in high growth companies in the 
medical and technology sectors, by using a focused, hands-on company building 
approach, based on decades of experience in both the US and UK. Amphion has a 
significant shareholding in ten Partner Companies developing proven technologies 
targeting substantial commercial marketplaces, each in excess of $1 billion. 
Each Partner Company is chosen with the goal of achieving an exit valuation in 
excess of $100 million. 
On the web: www.amphionplc.com 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSZDLFBKZBZBBE 
 

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024